DexCom, Inc. (DXCM)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for DXCM is $96.98, 12.7% above the last close of $86.04 on Oct 16, 2026; targets range from $76.10 to $117.55. Rating consensus: Buy.
Snapshot
- P/E34.0x
- P/E vs sector+20.8%
- P/E vs own+11.1%
- Target upside+12.7%
- ConsensusBuy
- Market cap$32.47B
- FCF yield+4.3%
- Insiders-$6.6M
- Earnings in13d
- News
Why it moved
DexCom, Inc. (DXCM) fell 1.9% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move is specific to DXCM.
1 story on the day (30-day average 0.5).
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $86.04 · +29.7% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendsideways
- Sector▲ +16.0%
- MAs20▼ 50▼ 100▲ 200▲
- Above MAs2 of 4 above
- MA20×50Death 9d ago
- RSI50
- Support-4.4%
- Resistance+0.4%
- Off 52w high-6.8%
- Off ATH-47.2%
- 52w range$86.04
- Bollingerlower half
- MACD0.04
- ATR+2.9%
- Volume1.0x
Analyst price targets
17 firms with a target in the last 12 months · last close $86.04 · as of Oct 16, 2026
Strong buy 4 · Buy 22 · Hold 3 · Sell 0 · Strong sell 0
Revenue and free cash flow
Q2 FY2026: Revenue +13.1% year over year, free cash flow 14.1% of revenue, operating margin 24.3%.
| Q2 FY2026 | Jun 30, 2026 | $1.31B | 0.64 | $185M | 63.4% | 24.3% | 19.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.19B | 0.51 | $449M | 62.9% | 21.4% | 16.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.26B | 0.68 | $192M | 62.9% | 25.6% | 21.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.21B | 0.70 | $579M | 60.5% | 20.1% | 23.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.16B | 0.45 | $209M | 59.5% | 18.4% | 15.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.04B | 0.27 | $96.8M | 56.9% | 12.9% | 10.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.11B | 0.38 | $177M | 58.9% | 17.0% | 13.6% |
| Q3 FY2024 | Sep 30, 2024 | $994M | 0.34 | $88.3M | 59.7% | 15.3% | 13.5% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $294.66 | +0.5% | -23.3% | +23.9% | 30.5 | $113B | |
| 2 |  | $44.39 | +0.6% | -57.7% | +50.1% | 18.0 | $64.33B | |
| 3 |  | $86.60 | -1.7% | -9.0% | +15.2% | 49.8 | $49.9B | |
| 4 | | $86.04 | -1.9% | -6.8% | +12.7% | 34.0 | $32.47B | |
| 5 |  | $69.57 | -1.1% | -21.0% | +20.2% | 20.2 | $31.42B | |
| 6 |  | $94.98 | +0.6% | -7.7% | +9.0% | 23.1 | $18.12B | |
| 7 |  | $147.31 | -1.4% | -25.4% | +35.1% | 25.6 | $10.46B | |
| 8 |  | $141.10 | +1.7% | -59.3% | +32.3% | 26.4 | $9.79B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.